The Pharmaceutical Contract Development and Manufacturing Organisation, Recipharm AB (publ) has acquired Lisbon based CDMO Lusomedicameta Sociedade Técnica Farmacêutica S.A. Highlights · Lusomedicamenta, together with its subsidiary, had twelve month revenues and adjusted EBITDA for non-recurring items to end September 2014 of EUR 50.7million (SEK 456.3 million) and EUR 12.7 million (SEK 114.3 million) respectively representing an adjusted margin of 25%. · The combined entity will enhance Recipharm’s scale and profitability. Based on LTM September 2014, the combined revenue and EBITDA (pre-Corvette) is SEK 2 725 million and SEK 446 million respectively. · The transaction values Lusomedicamenta at an enterprise value of EUR 112.3 million (SEK 1 040 million), which represents an adjusted EBITDA multiple of 8.8 based on LTM September 2014. The preliminary net debt is neglible. · The consideration has been paid in a combination of cash and newly issued RECI B shares. This represents EUR 67.1 million (SEK 621.6 million) in cash and 3 500 000 RECI B shares at a value of EUR 43.9 million (SEK 406.0 million). A further supplementary payment of EUR 1.3 million (SEK 12.0 million) will be paid in 2015 subject to the final 2014 performance of Lusomedicamenta. · Limited customer overlap and significant export activities from Lusomedicamenta, will give Recipharm access to new markets and customers. · Lusomedicamenta has an attractive and competitive cost structure, whilst located in the EU, and manufacturing operations well in line with international regulatory requirements. · Lusomedicamenta will contribute to Recipharm’s Intellectual Property (IP) backed manufacturing business as 30% of sales relate to IP rights including own marketing authorisations, mainly in the Portuguese market. · Accretive to Recipharm’s profitability and EPS already from Q1 2015. · The transaction was financed by already available credit facilities together with the new share issue. · The existing management and most of the former owners will continue for the foreseeable future in the company. Thomas Eldered, CEO of Recipharm: ”The acquisition of Lusomedicamenta represents an excellent addition to the Recipharm Group and is perfectly in line with our strategic plan to access new markets, establish new customer relationships and consolidate the industry to become a major CDMO. The new customer base combined with significant IP backed sales in Portugal provides us with many new exciting opportunities. I am particularly pleased that we have been able to reach agreement with the former owners of Lusomedicamenta who were working in the company to stay and take the company on to the next level together with us”. António Barros Ferreira, speaking on behalf of the sellers: “Since we took ownership of Lusomedicamenta in 2004 as a spinoff of a Janssen -Cilag facility, we have been very successful in creating and growing the business particularly in Portugal. We now have a strong export market and emerging business in Africa which we believe we will be able grow with Recipharm. I am very pleased that we are now becoming part of the Recipharm Group which will enable us to compete on a wider scale and provide many benefits to our customers”. About Lusomedicamenta Lusomedicamenta is primarily a CDMO specialised in the development and manufacture of solid, liquid and semi-solid dose forms as well as sterile ophthalmic products. It operates from two sites located close to Lisbon and has invested heavily in the production of effervescent tablets with a new dedicated facility for this purpose. The company is also focused on new products carrying the management of the whole process from product development to the registration dossier. Lusomedicamenta employs around 340 people and produces over 150 formulations in more than 600 SKU’s, exporting to some 45 countries worldwide. Transaction rationale Complements Recipharm’s existing business · Combined with Lusomedicamenta, Recipharm will be the one of strongest CDMO’s in Europe with added presence in south west Europe. Access to new customers, markets and technologies. · Little overlap of customers presenting good cross selling opportunities. · Lusomedicamenta has strong sales in Portugal and also in export markets including Africa where Recipharm is not present. · Adds several new interesting technologies and niches to Recipharm’s offering such as effervescent solid dose forms and sterile ophthalmic preparations. Own products business in Portugal. · A number of distribution agreements in the Portuguese market have been secured with companies such as Boehringer Ingelheim, Gedeon Richter and OM Pharma (Vifor). · Supports Recipharm’s ambition to have more sales based on an IP offering. Attractive financial impact. · Lusomedicamenta will increase Recipharm sales by 20 % and EBITDA margin by 32% based on YTD figures September 2014. · Lusomedicamenta has a history of strong sales and profitability development. · The acquisition is expected to be accretive to profitability and EPS · Given Lusomedicamenta’s attractive cost environment, additional non quantified benefits are expected to be realized, including optimization and specialization in Recipharm’s network for oral solids Transaction terms · The initial equity consideration of EUR 111 million has been paid, EUR 67.1 million in cash and EUR 43.9 million in RECI B equity in kind representing 3 500 000 shares. · The sellers of Lusomedicamenta have undertaken not to sell or otherwise assign or transfer 1 181 193 RECI B shares (lock-up) during the period commencing on the closing date and continuing to and including 13 November 2016 (i.e. two years after the closing date). The sellers have informed Recipharm that all RECI B shares not subject to the lock-up will be offered by Carnegie Investment Bank (“Carnegie”) to institutional investor in a private placement. In connection with the private placement, Thomas Eldered has agreed to lend up to 2,500,000 RECI B shares to Carnegie to facilitate settlement of the shares offered by Carnegie to institutional investors. · A further EUR 1.3 million may be paid in cash subject to the final outcome of 2014. · The transaction was financed by already available credit facilites together with new share issue. · Transaction costs are estimated to be less than EUR 1.5 million. Resolution by the Board of Directors of Recipharm to issue RECI B shares The Board of Directors has resolved, pursuant to the authorisation granted at the Extraordinary General Meeting held on 11 September 2014, to increase the Company’s share capital by up to SEK 1,750,000 through the issue of up to 3,500,000 new RECI B shares. The new shares may only be subscribed for by the shareholders in Lusomedicamenta with right and obligation of the subscriber to make payment for the shares subscribed for through contribution in kind of 1,600,000 shares in Lusomedicamenta. Proforma Financial Summary – End September 2014 +--------+---------+---------+---------+-----+-------+ |LTM Pf |Recipharm|Lusomed.1|Corvette2|Total|Change | |(mSEK) | | | | | | +--------+---------+---------+---------+-----+-------+ |Net |2 269 |456 |499 |3 224|42,1% | |turnover| | | | | | +--------+---------+---------+---------+-----+-------+ |EBITDA |332 |114 |130 |576 |73,5% | +--------+---------+---------+---------+-----+-------+ |EBITDA |14.6 |25.0 |26.1 |17.9 | | |margin %| | | | | | +--------+---------+---------+---------+-----+-------+ |1Based | | | | | |on an | | | | | |average | | | | | |EUR/SEK | | | | | |-rate of | | | | | |9,00 | | | | | +--------+---------+---------+---------+-----+-------+ |2Based | | | | |on an | | | | |average | | | | |EUR/SEK | | | | |-rate of | | | | |8.65 and | | | | |2013 FY | | | | |figures | | | | +--------+---------+---------+---------+-----+-------+ Nine month YTD 2014 PF (mSEK) Recipharm Lusomed.1 Total Change Net turnover 1 696 337 2 034 19,9% EBITDA 252 80 332 31,9% EBITDA margin % 14.8 23.8 16.3 1Based on an average EUR/SEK-rate of 9,04 Conference call and Q&A A conference call with a web presentation will be held at 0900hrs CET on 14th November 2015. To participate in the conference, please dial: From Sweden, tel: +46 8 506 443 86 From Denmark, tel: +45 32 71 42 62 From Finland, tel: +358 9 8171 0375 From Norway, tel: +47 21 06 61 13 From the UK, tel: +44 20 7153 9154 From Germany, tel: +49 69 2017 44 210 From France, tel: +33 1 70 70 95 02 From Spain, tel: +34 914 142 009 From Switzerland, tel: +41 44 580 65 22 From the US, tel:+1 877 423 0830 From Italy, tel: + +39 02 3600 6663 From Portugal, +49 69 20 17 44 210 Pin code for participants: 862216# To access the presentation use the following link: http://event.onlineseminarsolutions.com/r.htm...F476C044CC E 2004D68E488F For further information please visit www.recipharm.com or contact: Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10 Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 13 November, 2014, at 18:35 am CET. About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 1,750 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 250 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm’s turnover is approximately SEK 2.6 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain and Italy and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com (http://file///C:/Users/Thomas/AppData/Local/Microsoft/Windows / Temporary%20Internet%20Files/Content.Outlook/FZHEQOEB/visit%20www.recipharm.com) . Recipharm has retained Abreu Advogados in Portugal and Setterwalls Advokatbyrå AB in Sweden as legal advisors for the transaction. Carnegie Investment Bank acted financial advisors for the transaction. Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro, Sweden Telephone 46 8 602 52 00 Fax 46 8 81 87 03, www.recipharm.com
Recipharm acquires Lusomedicamenta for SEK 1 billion The
Top 10 Most Recent News Articles
LG Channels UAE Push Tests the Free Streaming Model
A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...
Continue Reading
Condo Downsizing Demands More Than a Price Check Today
A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...
Continue Reading
Housing's Value Equation Is Getting More Complicated
A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...
Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight
A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...
Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction
Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...
Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets
Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...
Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger
A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...
Continue Reading
Clarivate's 2026 Research List Carries a Trust Test
Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...
Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight
Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...
Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits
Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...
Continue ReadingTop 5 Most Recently Viewed Articles
T&T Supermarkets Expands Presence with New Store Opening
T&T Supermarkets Unveils Plans for a Major New Store T&T Supermarket Inc., Canada's largest Asian grocery retailer, is excited to share plans for their newest store in California, which will be located at Crossroads Marketplace in Chino Hills. This store will span an impressive 61,000 square feet, providing ample space for a wide variety of products and services to meet...
Continue Reading
Autohome Inc. Unveils its Comprehensive 2024 ESG Report
Autohome Inc. Releases 2024 ESG Report Autohome Inc. (NYSE: ATHM) has shared its 2024 Environmental, Social, and Governance (ESG) report. This document emphasizes the firm's commitment to sustainable practices and highlights their ongoing journey towards eco-friendly solutions within the automobile sector. Insights from the ESG Report The report details the extensive ESG...
Continue Reading
Nintendo and The Pokemon Company Pursue Legal Action Against Palworld
Nintendo and The Pokemon Company Take Legal Action Nintendo and The Pokemon Company have officially initiated a patent infringement lawsuit against the creators of the popular survival adventure game, "Palworld." This development has caught the attention of both gamers and industry experts alike. Details of the Lawsuit Reports indicate that the lawsuit was filed on...
Continue Reading
NYCM Insurance Achieves Elite Winner Status for Wellness
NYCM Insurance Celebrated for Wellness Excellence NYCM Insurance proudly announces its recognition as an "Elite Winner" among the Nation's Best and Brightest in Wellness. This marks an outstanding milestone for the company, achieving the accolade for the twelfth consecutive year, a testament to their dedication to enhancing employee wellness. Commitment to Employee...
Continue Reading
Antonio Filosa Leads Stellantis with Newly Formed Team
New Leadership Structure at Stellantis Under Antonio Filosa Today marks a significant milestone for Stellantis N.V. as Antonio Filosa steps into the role of Chief Executive Officer. Alongside this transition, he has unveiled an exciting new leadership team, showcasing a strong lineup of industry veterans and decision-makers from across Stellantis’ diverse operations...
Continue Reading